WGS (GeneDx Holdings) Asset Impairment Charge: $31.3 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WGS GeneDx Holdings Corp WGS
66 GF Score
Price $89.74
GF Value $74.08
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is GeneDx Holdings Asset Impairment Charge?

GeneDx Holdings WGS +5.26% 66 Asset Impairment Charge is $31.3 Mil as of Jun. 2026. GuruFocus rates WGS with a GF Score™ of 66/100 and a GF Value™ of $74.08 (Modestly Overvalued). The stock has 3 warning signs investors should review.

GeneDx Holdings's Asset Impairment Charge for the three months ended in Jun. 2026 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was $31.3 Mil.

GeneDx Holdings Asset Impairment Charge Related Terms

GeneDx Holdings Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for GeneDx Holdings's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneDx Holdings Asset Impairment Charge Chart

GeneDx Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial 0.00 210.15 10.40 0.00 0.00

GeneDx Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 31.29 0.00
WGS
66GF Score
GeneDx Holdings Corp WGS
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneDx Holdings Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.3 Mil.

What does a Asset Impairment Charge of $31.3 Mil mean?
GeneDx Holdings (WGS) has a Asset Impairment Charge of $31.3 Mil as of Jun. 2026.
Is GeneDx Holdings' Asset Impairment Charge too high?
GeneDx Holdings' current Asset Impairment Charge is $31.3 Mil. Overall, GeneDx Holdings has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' Asset Impairment Charge compare to CDNA and NEO?
GeneDx Holdings' Asset Impairment Charge of $31.3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Medical Diagnostics & Research company?
A good Asset Impairment Charge depends on the Medical Diagnostics & Research industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. GeneDx Holdings's current Asset Impairment Charge is $31.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Modestly Overvalued. The stock's GF Value™ is $74.08, compared to a current price of $89.74 — trading 21.1% above its estimated fair value. The current Asset Impairment Charge is $31.3 Mil. GeneDx Holdings' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current Asset Impairment Charge is $31.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneDx Holdings (WGS) Overvalued in 2026?

Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued. The current stock price of $89.74 is trading 21.1% above its estimated GF Value™ of $74.08. GuruFocus considers GeneDx Holdings to be Modestly Overvalued.

Key valuation signals for WGS:

  • Asset Impairment Charge: $31.3 Mil
  • GF Value™: $74.08 vs. price of $89.74 (21.1% above fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GeneDx Holdings Business Description

Address 333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
66GF Score

Get the complete analysis for WGS

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.74
Price
$74.08
GF Value